TSC2 and acute myeloid leukemia: Our analysis revealed that the AML master driver oncogene MITF23 was significantly upregulated in TSC2−/− iPSC-derived Day-21 organoids, compared to TSC2+/− and TSC2+/+ iPSC-derived organoids (Fig. 1g).